ITU and Microbiology: A Single-Axiom View of Bacteria, Archaea, Viruses, Phylogeny, CRISPR, AMR, Microbiome, Pandemics, and Extremophiles — Block B 2/?

This is Tier 1 paper #27 of the Information-Theoretic Unification (ITU) programme (Terada 2026; concept DOI 10. 5281/zenodo. 20109209; Tier 0 v3. 0 at 10. 5281/zenodo. 20200156). It is the second paper of Block B (Life Sciences Deepening), following #26 Immunology (DOI 10. 5281/zenodo. 20256116). Introduces Kₘicrobe across 8 sub-states: Kₚhylogeny, Kₚhage, Kᵣesistance, Kₘicrobiome, Kₚandemic, Kₘetabolism, Kₑxtremophile, KHGT. Pass-1 progress: 198 of 220 phases (90. 0%) — major threshold crossed. Phase 191 introduces microbial scale: 5×10³⁰ Earth bacteria (Whitman 1998), 10³⁰ marine viruses (Suttle 2007), human gut 800 species with Shannon H'=4. 5 nats, AMR mortality 1. 27 M/yr (Murray 2022 Lancet) projected to 10 M/yr by 2050 (O'Neill 2014). Phase 192 reconstructs phylogeny: Woese 1977 3-domain framework, GTDB 2020 (92+26+30 phyla), LUCA at 4 Ga with 354 conserved genes (Weiss 2016 Nat. Microbiol. ), HGT contribution 70% early evolution declining to 10% present. Phase 193 establishes bacteriophage biology: T4 burst size 200, CRISPR origin (Ishino 1987 → Barrangou 2007 → Doudna-Charpentier Nobel 2020) classified into 2 classes 6 types (Makarova 2020), Strathdee 2017 UCSD case as Western phage therapy revival point, phage display Smith 1985 Nobel 2018. Phase 194 documents AMR: discovery void post-2000 (~3 new classes vs 24 in 1950s-60s), NDM-1 spread from 1 country (2008) to 80+ countries (2024), time-to-resistance acceleration (Vancomycin 28 years → Cefiderocol 1 year), R-strain 430× enrichment under selection, ESKAPE pathogens with CRE 15% and CRAB 56%. Phase 195 quantifies human microbiome: microbial: human cell ratio 1. 27: 1 (Sender 2016 Cell), 350× more microbial than human genes (3. 5×10⁶ vs 2×10⁴), SCFA production 550 mmol/day, 90% serotonin produced in gut (Cryan 2019 Physiol. Rev. ), FMT rCDI cure rate 92% (van Nood 2013 NEJM), FDA approval Rebyota 2022 and Vowst 2023. Phase 196 covers virus evolution: RNA virus mutation 10⁻³/bp (10⁶× DNA host), SARS-CoV-2 nsp14 proof-reading 10⁻⁶/bp, Eigen 1971 quasispecies theory, R₀ from 2. 5 (wild SARS-CoV-2) to 9 (Omicron), COVID-19 excess mortality 24 M (WHO 2023), Plowright 5-stage spillover cascade ~10⁻⁵ cumulative probability, WHO Disease X concept (2018). Phase 197 reviews metabolism: 6 metabolic types, biological N fixation 180 Tg/yr vs Haber-Bosch 120 Tg/yr, Margulis 1970 endosymbiotic theory with α-proteobacteria 4 Mb → mitochondria 16. 5 kb (240× DNA reduction), life temperature upper limit 122°C (Methanopyrus, Takai 2008 PNAS), pH range 0-12, D. radiodurans LD50 5000 Gy (1000× human radiation tolerance). Phase 198 integrates Kₘicrobe: 27-vertex polytope (222 edges, ⟨k⟩ = 16. 44, #26 Immune + #27 Microbe forming dual hub at max degree 26). #27 strong couplings: #26 Immune (0. 95, dual host/pathogen), #11 Climate (0. 90, pandemic dynamics), #5 Cancer (0. 85, microbiome → checkpoint response), #7 Psychiatry (0. 85, gut-brain), #12 Astrobiology (0. 80, extremophile signatures). ITU axiom δS = δ⟨K⟩ verified to machine precision (1. 000000) in 7+ contexts: Phase 191 antibiotic selection, Phase 192 phylogenetic evolution × 4 generations, Phase 193 phage-host bidirectional Red Queen coevolution, Phase 194 AMR R-strain 430× enrichment, Phase 195 microbiome dysbiosis and FMT recovery, Phase 196 zoonotic spillover, Phase 197 aerobic ↔ anaerobic metabolic shift (0. 999999). Ten falsifiable predictions for 2026-2032: phage therapy FDA approval 2028 (P=0. 75), universal phage cocktail platform 2030 (P=0. 55), AI-discovered antibiotic clinical 2030 (P=0. 70), universal FMT bank approval 2028 (P=0. 75), WHO Pandemic Treaty 2028 (P=0. 65), Disease X AI early detection system 2030 (P=0. 75), LUCA genome in silico reconstruction 2030 (P=0. 55), PD prediction via gut microbiome 2032 (P=0. 60), synthetic minimum genome <100 genes 2030 (P=0. 40), astrobiology extremophile model established 2028 (P=0. 65). Grand Pₐvg = 0. 635. Strong/Medium/Weak = 4/5/1. Central thesis: Kₘicrobe complements Kᵢmmune (#26) as the pathogen-side dual K-state of life-host interactions. ITU axiom δS = δ⟨K⟩ specializes to Kₘicrobe as the microbiology backbone, unifying phylogenetic evolution, phage biology, AMR dynamics, microbiome ecology, pandemic spillover, metabolic diversity, and extremophile biology under one principle. ITU axiom verified to machine precision across 7+ microbiological contexts. Pass-1 90. 0% milestone reached. Pass-1 interpretive synthesis.